Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...
First-line treatment with chemotherapy, bevacizumab, and atezolizumab led to a statistically significant improvement in progression-free survival (PFS) compared with atezolizumab alone in patients ...
When researchers look for potential cancer therapy targets, they typically go after protein-coding genes that participate in disease progression. Disrupt them and negate whatever role they play in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results